BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33973071)

  • 1. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Aso S; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Int J Rheum Dis; 2022 May; 25(5):576-583. PubMed ID: 35258165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N; Suzuki T; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H
    JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R; Inuzuka R; Shindo T; Namai Y; Oda Y; Harita Y; Oka A
    Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
    Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
    Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J; Su D; Yuan P; Ye B; Qin S; Pang Y
    Cardiology; 2023; 148(5):457-468. PubMed ID: 37231847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin preparations affect hyponatremia in Kawasaki disease.
    Kaneko K; Hirabayashi M; Tateiwa A; Shimo T; Teranishi K; Tanaka S; Yoshimura K; Kino M; Okazaki H; Harada Y
    Eur J Pediatr; 2010 Aug; 169(8):957-60. PubMed ID: 20165868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
    Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J; Ye B; Su D; Qin S; Zhao W; Pang Y
    Clin Rheumatol; 2023 Jan; 42(1):167-177. PubMed ID: 36129563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.